The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-27. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
== Further reading == Genck, Wayne (7 November 2010). "Make The Most of Antisolvent Crystallization". Chemical Processing. Putman Media. Retrieved 12 June 2025. Sheehan, David (2009). Physical Biochemistry: Principles and Applications. John Wiley & Sons. p. 285. ISBN 978-0-470-85602-4. Miller, S A; Dykes, D D; Polesky, H F (11 February 1988). "A simple salting out procedure for extracting DNA from human nucleated cells". Nucleic Acids Research. 16 (3): 1215. CiteSeerX 10.1.1.941.1917. doi:10.1093/nar/16.3.1215. PMC 334765. PMID 3344216. {{cite journal}}: Cite uses deprecated parameter |citeseerx= (help) McKay, H. A. C. (1 January 1953). "Activities and activity coefficients in ternary systems". Transactions of the Faraday Society. 49: 237–242. doi:10.1039/TF9534900237.
A mixer-settler consists of a mixing stage that often forms a suspension of two immiscible liquids followed by a settling stage that allows the liquids to separate into two layers by gravity. Mixer-settlers are typically used when a process requires longer residence times and when the solutions are easily separated by gravity. In a multistage countercurrent process, multiple mixer-settlers are installed in series with the settled output of one stage being fed to subsequent stages for further separation.
Two of his bodyguards and a female pedestrian were killed in the assassination attempt as well. While Tweeting from his hospital bed, Garcia blamed the CJNG for the failed attempt on his life and had 12 suspected CJNG members arrested by the end of the day. The same day, it emerged that the CJNG still controlled organized crime in Jalisco, Guanajuato, Querétaro, Hidalgo, but no longer was listed as having such control in any municipality in Veracruz and still was unable to take away territory in other parts of southeastern Mexico controlled by the Sinaloa Cartel, Los Zetas and the so-called Los Pelones group. Sánchez was later murdered, with his body being discovered stabbed and wrapped in plastic on a park bench in downtown Tlaquepaque on 18 March 2021. Emilio Alejandro Pulido Salazar would surrender to Mexican authorities the same month. Érick Valencia Salazar, alias "El 85", was presumed to be the head of the Nuevo Plaza Cartel at the time of El Cholo's death. In February 2022, leading CJNG operator in Michoacán and trusted El Mencho associate Miguel Ángel Fernández, known as "El M2", was found murdered in the town of Cansangüe, located in the municipality of Tepalcatepec El 85 was later captured by Mexican authorities in September 2022. By November 2021, El Mencho and his wife Rosalinda's younger sisters were the only CJNG members to remain at large who were also among the cartel's original founders. In May 2022, Insight Crime reporter Peter Appleby reported that El Mencho's poor health, and also rumored death, accelerated break-ups and infighting in the CJNG.
Neuropeptides are chemical messengers made up of small chains of amino acids that are synthesized and released by neurons. Neuropeptides typically bind to G protein-coupled receptors (GPCRs) to modulate neural activity and other tissues like the gut, muscles, and heart. Neuropeptides are synthesized from large precursor proteins which are cleaved and post-translationally processed then packaged into large dense core vesicles. Neuropeptides are often co-released with other neuropeptides and neurotransmitters in a single neuron, yielding a multitude of effects. Once released, neuropeptides can diffuse widely to affect a broad range of targets. Neuropeptides are extremely ancient and highly diverse chemical messengers. Placozoans such as Trichoplax, extremely basal animals which do not possess neurons, use peptides for cell-to-cell communication in a way similar to the neuropeptides of higher animals.
== Interactions == Naltrexone, a non-selective opioid receptor antagonist including of the κ-opioid receptor (KOR), blocks the hallucinogenic and physiological effects of salvinorin A in humans. Conversely, the serotonin 5-HT2A receptor antagonist ketanserin was ineffective.
Sources: en.wikipedia.org
==== United States ==== In the United States, immediate-release injectable nalmefene was approved in 1995, as an antidote for opioid overdose. It was sold under the brand name Revex. The product was discontinued by its manufacturer around 2008. A generic version was approved for medical use in the United States in February 2022. In May 2023, the Food and Drug Administration (FDA) approved a nalmefene hydrochloride nasal spray, under the brand name Opvee, for the emergency treatment of opioid overdose in people aged twelve years of age and older. In August 2024, the FDA approved a nalmefene hydrochloride auto-injector (Zurnai) for the emergency treatment of known or suspected opioid overdose in people aged twelve years of age and older. The FDA granted the application for the nalmefene hydrochloride auto-injector fast track and priority review designations. The FDA granted approval of Zurnai to Purdue Pharma L.P. As of 2012, nalmefene in pill form, used for the treatment of alcohol dependence and other addictive behaviors, is not available in the United States.
Improving metabolism (improving insulin sensitivity, inhibiting de novo lipogenesis, or increasing fatty acid oxidation). Metabolic modulators tested in MASH include glucagon-like peptide-1 receptor agonists (GLP-1 agonists), GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) or glucagon co-agonists and thyromimetics. Some of these drugs may treat MASFLD by significantly reducing body weight. Reducing inflammation, for example reducing oxidative stress and hepatocyte death. These drugs, such as chemokine antagonists, anti-apoptotics, vascular adhesion protein-1 inhibitors, and c-Jun N-terminal kinase inhibitors, have not shown benefit. "Gut-liver axis targets" that either change a person's microbiome, or act on bile acids Anti-fibrotic drugs, such as fibroblast growth factor analogues, which have largely not met their endpoints Other treatments such as farnesoid X receptor (FXR) agonists, peroxisome proliferator-activated receptor (PPAR) agonists, and ASK1 (apoptosis signal-regulating kinase 1) inhibitors may improve MASFLD by multiple mechanisms simultaneously.
Trazodone has been studied as an adjunctive therapy in the treatment of schizophrenia. It has been reported to decrease negative symptoms without worsening positive symptoms although improvement in negative symptoms was modest. Trazodone has also been reported to be effective in treating antipsychotic-related extrapyramidal symptoms such as akathisia. Trazodone has been studied and reported to be effective in the treatment of bulimia, but there is limited evidence to support this use. It might be useful in the treatment of night eating disorder as well. Trazodone might be effective in the treatment of adjustment disorder. It may also be effective in the treatment of bruxism in children and adolescents. Trazodone may be useful in the treatment of certain chronic pain disorders. There is limited but conflicting evidence to support the use of trazodone in the treatment of headaches and migraines in children. Trazodone may be useful in the treatment of fibromyalgia as well as diabetic neuropathy. It may also be useful in the treatment of burning mouth syndrome. A 2004 narrative review claimed that trazodone could be used in the treatment of complex regional pain syndrome. Trazodone may also be effective in the treatment of functional gastrointestinal disorders. It may be effective in the treatment of non-cardiac chest pain as well. Trazodone may be useful in promoting motor recovery after stroke. Trazodone is sometimes prescribed to treat premature ejaculation but clomipramine and paroxetine may be more effective.
As the first woman since 1964 to win the Nobel Prize in chemistry, and the first since Dorothy Crowfoot Hodgkin, 45 years previously. She was also the fourth of eight women ever to win the Nobel Prize in chemistry. Although Yonath once remarked, “I am a scientist, not male or female. A scientist,” her 2009 award was noted as a highlight for female scientists. The Australian noted that Yonath's Nobel win was "crushing the lab's glass ceiling". Regarded as an influential Israeli scientist, Yonath helped established the first protein crystallography laboratory in Israel. In 2018, while interviewing Yonath, UNESCO noted that her scientific research has also been "key to understanding how antibiotics work". Following her death, The New York Times noted that Yonath's mapping of the ribosome led to new designs for antibiotics. Her work was noted as "boundary pushing" with it having "immediate and practical consequences" for medicine and in the "fight against infectious disease". President Isaac Herzog noted Yonath as "one of the leading researchers in the history of Israeli science". The Hindu also noted Yonath's academic impact, especially in India through her engagements in academic institutions in the country.
Sources: en.wikipedia.org
=== For the political right === Both liberals and neoconservatives in the United States celebrated the dissolution of the Soviet Union. Ideas such as Francis Fukuyama's end of history and Charles Krauthammer's unipolar moment gained prominence to describe the victory of Western liberal democracy. At the same time, both sides of the political spectrum in the US criticized the George H. W. Bush administration for its comparative cautiousness and political support of Gorbachev over more pro-democracy and nationalist forces in the Soviet Union.
=== Crop development === Given the enormous damage that citrus canker, citrus greening, bacterial soft rot and wildfire disease cause to food and cash crops each year, there is interest in developing new plant varieties that are more resistant to infection. One possible solution is to enhance the natural defenses of crops using antimicrobial peptides. Necrophagous insects are a rich source of these peptides, and transgenic research in Japan, the USA, and Brazil has shown that sarcotoxin IA (from Sarcophaga peregrina) can help protect orange trees and other crops.
Joanna Bryson and Helena Malikova have pointed to Big Tech's potential interest in promoting the AI Cold War narrative, as technology companies lobby for less onerous regulation of AI in the US and the EU. A factual assessment of the existing AI capabilities of different countries shows a less binary reality than portrayed by the AI Cold War narrative. The AI Cold War started as a narrative but it could turn into a self-fulfilling prophecy and fuel an arms race, not only because of corporate interests but also because of the existing interests at different national security departments. Regarding cyber power, the International Institute for Strategic Studies published a study in June 2021, which argued that the online capabilities of China have been exaggerated and that Chinese cyber power is at least a decade behind the US, largely due to lingering security issues.
== N == Neotropic cormorant - the Uru people domesticated the neotropic cormorant(an aquatic bird). Nixtamalization – the process originated in Mesoamerica, with the earliest evidence of its presence found in Guatemala's southern coast with equipment dated to 1200-1500 BCE.
=== EC 2.8.3: CoA-transferases === EC 2.8.3.1: propionate CoA-transferase EC 2.8.3.2: oxalate CoA-transferase EC 2.8.3.3: malonate CoA-transferase EC 2.8.3.4: deleted EC 2.8.3.5: 3-oxoacid CoA-transferase EC 2.8.3.6: 3-oxoadipate CoA-transferase EC 2.8.3.7: The activity is due to two enzymes, EC 2.8.3.22, succinyl-CoA—L-malate CoA-transferase and EC 2.8.3.20, succinyl-CoA—Dcitramalate CoA-transferase EC 2.8.3.8: acetate CoA-transferase EC 2.8.3.9: butyrate—acetoacetate CoA-transferase EC 2.8.3.10: citrate CoA-transferase EC 2.8.3.11: citramalate CoA-transferase EC 2.8.3.12: glutaconate CoA-transferase EC 2.8.3.13: succinate—hydroxymethylglutarate CoA-transferase EC 2.8.3.14: 5-hydroxypentanoate CoA-transferase EC 2.8.3.15: succinyl-CoA:(R)-benzylsuccinate CoA-transferase EC 2.8.3.16: formyl-CoA transferase EC 2.8.3.17: cinnamoyl-CoA:phenyllactate CoA-transferase EC 2.8.3.18: succinyl-CoA:acetate CoA-transferase EC 2.8.3.19: CoA:oxalate CoA-transferase EC 2.8.3.20: succinyl-CoA—D-citramalate CoA-transferase EC 2.8.3.21: L-carnitine CoA-transferase EC 2.8.3.22: succinyl-CoA—L-malate CoA-transferase EC 2.8.3.23: caffeate CoA-transferase EC 2.8.3.24: (''R'')-2-hydroxy-4-methylpentanoate CoA-transferase EC 2.8.3.25: bile acid CoA-transferase EC 2.8.3.26: succinyl-CoA:mesaconate CoA transferase
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.